Heidi M. Crane

Heidi M. Crane

Auto-generated profile, based on publicly available information

Heidi M. Crane

University of Washington, Seattle, WA, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2020 in Journal of the International AIDS Society
Verified
Journal Article
Open access
PDF file
KBKassem Bourgi
Kassem Bourgi
CJCathy A Jenkins
Cathy A Jenkins
PRPeter F Rebeiro
Peter F Rebeiro
BSBryan E. Shepherd
Bryan E. Shepherd
FPFrank Palella
Frank Palella
F(for the North American AIDS Cohort Collaboration on Research and Design (NA‐ACCORD)
for the North American AIDS Cohort Collaboration on Research and Design (NA‐ACCORD)
Introduction: Weight gain following antiretroviral therapy (ART) initiation is common, potentially predisposing some persons with HIV (PWH) to cardio‐metabolic disease. We assessed relationships between ART drug class and weight change among treatment‐naïve PWH initiating ART in the North American AIDS Cohort Collaboration on Research and Design (NA‐ACCORD).Methods: Adult, treatment‐naïve PWH in NA‐ACCORD initiating integrase strand transfer inhibitor (INSTI), protease inhibitor (PI) or non‐nucleoside reverse‐transcriptase inhibitor (NNRTI)‐based ART on/after 1 January 2007 were followed through 31 December 2016. Multivariate linear mixed effects models estimated weight up to five years after ART initiation, adjusting for age, sex, race, cohort site, HIV acquisition mode, treatment year, and baseline weight, plasma HIV‐1 RNA level and CD4+ cell count. Due to shorter follow‐up for PWH receiving newer INSTI drugs, weights for specific INSTIs were estimated at two years. Secondary analyses using logistic regression and all covariates from primary analyses assessed factors associated with >10% weight gain at two and five years.Results: Among 22,972 participants, 87% were male, and 41% were white. 49% started NNRTI‐, 31% started PI‐ and 20% started INSTI‐based regimens (1624 raltegravir (RAL), 2085 elvitegravir (EVG) and 929 dolutegravir (DTG)). PWH starting INSTI‐based regimens had mean estimated five‐year weight change of +5.9kg, compared to +3.7kg for NNRTI and +5.5kg for PI. Among PWH starting INSTI drugs, mean estimated two‐year weight change was +7.2kg for DTG, +5.8kg for RAL and +4.1kg for EVG. Women, persons with lower baseline CD4+ cell counts, and those initiating INSTI‐based regimens had higher odds of >10% body weight increase at two years (adjusted odds ratio = 1.37, 95% confidence interval: 1.20 to 1.56 vs. NNRTI).Conclusions: PWH initiating INSTI‐based regimens gained, on average, more weight compared to NNRTI‐based regimens. This phenomenon may reflect heterogeneous effects of ART agents on body weight regulation that require further exploration.

11 March 2017 in AIDS and Behavior
Verified
Journal Article
Closed access
PDF file
HCHeidi M. Crane
Heidi M. Crane
MMMary E. McCaul
Mary E. McCaul
GCGeetanjali Chander
Geetanjali Chander
HHHeidi Hutton
Heidi Hutton
RNRobin M. Nance
Robin M. Nance
MKMari M. Kitahata
Mari M. Kitahata

18 September 2018 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
RNRobin M. Nance
Robin M. Nance
JDJ.A. Chris Delaney
J.A. Chris Delaney
JSJane M. Simoni
Jane M. Simoni
IWIra B. Wilson
Ira B. Wilson
KMKenneth H. Mayer
Kenneth H. Mayer
HCHeidi M. Crane
Heidi M. Crane
Because HIV viral suppression is essential for optimal outcomes and prevention efforts, understanding trends and predictors is imperative to inform public health policy. To evaluate viral suppression trends in people living with HIV (PLWH), including the relationship of associated factors, such as demographic characteristics and integrase strand transfer inhibitor (ISTI) use. Longitudinal observational cohort study. 8 HIV clinics across the United States. PLWH receiving clinical care. To understand trends in viral suppression (≤400 copies/mL), annual viral suppression rates from 1997 to 2015 were determined. Analyses were repeated with tests limited to 1 random test per person per year and using inverse probability of censoring weights to address loss to follow-up. Joint longitudinal and survival models and linear mixed models of PLWH receiving antiretroviral therapy (ART) were used to examine associations between viral suppression or continuous viral load (VL) levels and demographic factors, substance use, adherence, and ISTI use. Viral suppression increased from 32% in 1997 to 86% in 2015 on the basis of all tests among 31 930 PLWH. In adjusted analyses, being older (odds ratio [OR], 0.76 per decade [95% CI, 0.74 to 0.78]) and using an ISTI-based regimen (OR, 0.54 [CI, 0.51 to 0.57]) were associated with lower odds of having a detectable VL, and black race was associated with higher odds (OR, 1.68 [CI, 1.57 to 1.80]) (P < 0.001 for each). Similar patterns were seen with continuous VL levels; when analyses were limited to 2010 to 2015; and with adjustment for adherence, substance use, or depression. Results are limited to PLWH receiving clinical care. HIV viral suppression rates have improved dramatically across the United States, which is likely partially attributable to improved ART, including ISTI-based regimens. However, disparities among younger and black PLWH merit attention. National Institutes of Health.

15 August 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ATAdam Trickey
Adam Trickey
MMMargaret T. May
Margaret T. May
JVJanne Vehreschild
Janne Vehreschild
NONiels Obel
Niels Obel
MGMichael John Gill
Michael John Gill
A(Antiretroviral Therapy Cohort Collaboration (ART-CC)
Antiretroviral Therapy Cohort Collaboration (ART-CC)
To estimate mortality rates and prognostic factors in HIV-positive patients who started combination antiretroviral therapy between 1996–1999 and survived for more than ten years. We used data from 18 European and North American HIV cohort studies contributing to the Antiretroviral Therapy Cohort Collaboration. We followed up patients from ten years after start of combination antiretroviral therapy. We estimated overall and cause-specific mortality rate ratios for age, sex, transmission through injection drug use, AIDS, CD4 count and HIV-1 RNA. During 50,593 person years 656/13,011 (5%) patients died. Older age, male sex, injecting drug use transmission, AIDS, and low CD4 count and detectable viral replication ten years after starting combination antiretroviral therapy were associated with higher subsequent mortality. CD4 count at ART start did not predict mortality in models adjusted for patient characteristics ten years after start of antiretroviral therapy. The most frequent causes of death (among 340 classified) were non-AIDS cancer, AIDS, cardiovascular, and liver-related disease. Older age was strongly associated with cardiovascular mortality, injecting drug use transmission with non-AIDS infection and liver-related mortality, and low CD4 and detectable viral replication ten years after starting antiretroviral therapy with AIDS mortality. Five-year mortality risk was <5% in 60% of all patients, and in 30% of those aged over 60 years. Viral replication, lower CD4 count, prior AIDS, and transmission via injecting drug use continue to predict higher all-cause and AIDS-related mortality in patients treated with combination antiretroviral therapy for over a decade. Deaths from AIDS and non-AIDS infection are less frequent than deaths from other non-AIDS causes.

26 July 2022 in Addiction Science & Clinical Practice
Verified
Journal Article
Open access
PDF file
RJRichard A. Jenkins
Richard A. Jenkins
BWBridget M. Whitney
Bridget M. Whitney
RNRobin M. Nance
Robin M. Nance
TATodd M. Allen
Todd M. Allen
HCHannah L. F. Cooper
Hannah L. F. Cooper
TIThe Rural Opioid Initiative
The Rural Opioid Initiative
Objective: To characterize and address the opioid crisis disproportionately impacting rural U.S. regions. Methods: The Rural Opioid Initiative (ROI) is a two-phase project to collect and harmonize quantitative and qualitative data and develop tailored interventions to address rural opioid use. The baseline quantitative survey data from people who use drugs (PWUD) characterizes the current opioid epidemic (2018–2020) in eight geographically diverse regions. Results: Among 3,084 PWUD, 92% reported ever injecting drugs, 86% reported using opioids (most often heroin) and 74% reported using methamphetamine to get high in the past 30 days; 53% experienced homelessness in the prior 6 months; and 49% had ever overdosed. Syringe service program use varied by region and 53% had ever received an overdose kit or naloxone prescription. Less than half (48%) ever received medication for opioid use disorder (MOUD). Conclusions: The ROI combines data across eight rural regions to better understand drug use including drivers and potential interventions in rural areas with limited resources. Baseline ROI data demonstrate extensive overlap between opioid and methamphetamine use, high homelessness rates, inadequate access to MOUD, and other unmet needs among PWUD in the rural U.S. By combining data across studies, the ROI provides much greater statistical power to address research questions and better understand the syndemic of infectious diseases and drug use in rural settings including unmet treatment needs.

1 March 2017 in JAMA Cardiology
Verified
Journal Article
Open access
PDF file
HCHeidi M. Crane
Heidi M. Crane
PPPathmaja Paramsothy
Pathmaja Paramsothy
DDDaniel R. Drozd
Daniel R. Drozd
RNRobin M. Nance
Robin M. Nance
JDJ. A. Chris Delaney
J. A. Chris Delaney
FCfor the Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) Cohort
for the Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) Cohort
There are many unanswered questions regarding the risk of cardiovascular disease (CVD), including myocardial infarction (MI), in human immunodeficiency virus (HIV)–infected individuals. Studies have suggested that rates of MIs may be higher in HIV-infected individuals vs those without HIV.1-4 Human immunodeficiency virus may affect lipid levels and endothelial function, leading to increased risk of CVD.5-7 Antiretroviral therapy (ART) has reduced HIV-associated morbidity and mortality,8-11 but some ART agents, particularly older ones, may increase the risk of CVD.12-15 Previous studies have used unadjudicated MI outcomes and have not differentiated the types of MI.1,16,17 These limitations may have contributed to conflicting findings regarding CVD risk in HIV-infected populations.